Taysha Gene Therapies (TSHA) Debt to Equity (2022 - 2025)
Historic Debt to Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $0.23.
- Taysha Gene Therapies' Debt to Equity fell 5201.47% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.23, marking a year-over-year decrease of 5201.47%. This contributed to the annual value of $0.61 for FY2024, which is 1365.21% up from last year.
- Taysha Gene Therapies' Debt to Equity amounted to $0.23 in Q3 2025, which was down 5201.47% from $0.17 recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Debt to Equity ranged from a high of $40.01 in Q4 2022 and a low of -$3.65 during Q3 2023
- Over the past 4 years, Taysha Gene Therapies' median Debt to Equity value was $0.54 (recorded in 2023), while the average stood at $2.81.
- Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 44648.68% in 2023, then skyrocketed by 13362.95% in 2024.
- Over the past 4 years, Taysha Gene Therapies' Debt to Equity (Quarter) stood at $40.01 in 2022, then crashed by 98.65% to $0.54 in 2023, then grew by 13.65% to $0.61 in 2024, then tumbled by 62.2% to $0.23 in 2025.
- Its Debt to Equity was $0.23 in Q3 2025, compared to $0.17 in Q2 2025 and $0.77 in Q1 2025.